Last reviewed · How we verify

Pertuzumab (ZRC-3277)

Zydus Lifesciences Limited · Phase 3 active Biologic

Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.

Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling. Used for HER2-positive metastatic breast cancer (in combination with trastuzumab and chemotherapy), HER2-positive gastric or gastroesophageal junction cancer.

At a glance

Generic namePertuzumab (ZRC-3277)
SponsorZydus Lifesciences Limited
Drug classHER2-targeted monoclonal antibody
TargetHER2 (Human Epidermal Growth Factor Receptor 2)
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Pertuzumab targets the extracellular domain II of HER2, a different epitope than trastuzumab, and prevents HER2 from forming heterodimers with HER3 and other HER family members. This dual mechanism—blocking both HER2 signaling directly and preventing ligand-induced dimerization—provides complementary inhibition of HER2-driven proliferation in cancer cells. It is often used in combination with trastuzumab and chemotherapy for enhanced efficacy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: